KIDS Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2016βFY2025
Orthopediatrics Corp had $236M of revenue in fiscal 2025, up 15.4% on the year before. Over five years, revenue changed +27.2% a year on average.
Last close Β· Oct 23, 2026
$24.50
0.8%Hi! I read Orthopediatrics Corpβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+15.4%
Yes. Sales grew 15.4% last year.
Does it make a profit?
β16.8%
No. It lost money last year.
Does profit turn into cash?
β6.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Orthopediatrics Corp had $236M of revenue in fiscal 2025, up 15.4% on the year before. Over five years, revenue changed +27.2% a year on average. Its operating margin was β16.6%, up 0.5Β pts: of every 100 in sales, about β17 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Orthopediatrics Corp lost $39.6M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$16.0M in fiscal 2025, β6.8% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $32.2M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$32.2M
7 insiders
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | David R PelizzonDirector, 10% owner | Sold | 302,369 | $21.01 | $6.4M | Form 4 |
| Sep 10, 2026 | Jennifer N. Pritzker10% owner | Sold | 302,369 | $21.01 | $6.4M | Form 4 |
| Sep 2, 2026 | David R PelizzonDirector, 10% owner | Sold | 22,500 | $23.35 | $0.5M | Form 4 |
| Sep 2, 2026 | Jennifer N. Pritzker10% owner | Sold | 22,500 | $23.35 | $0.5M | Form 4 |
| Sep 1, 2026 | David R PelizzonDirector, 10% owner | Sold | 10,131 | $23.10 | $0.2M | Form 4 |
| Sep 1, 2026 | Jennifer N. Pritzker10% owner | Sold | 10,131 | $23.10 | $0.2M | Form 4 |
| Aug 28, 2026 | David R PelizzonDirector, 10% owner | Sold | 326,700 | $23.04 | $7.5M | Form 4 |
| Aug 28, 2026 | Jennifer N. Pritzker10% owner | Sold | 326,700 | $23.04 | $7.5M | Form 4 |
| Aug 26, 2026 | David R PelizzonDirector, 10% owner | Sold | 18,000 | $24.28 | $0.4M | Form 4 |
| Aug 26, 2026 | Jennifer N. Pritzker10% owner | Sold | 18,000 | $24.28 | $0.4M | Form 4 |
| Aug 25, 2026 | David R PelizzonDirector, 10% owner | Sold | 16,300 | $24.74 | $0.4M | Form 4 |
| Aug 25, 2026 | Jennifer N. Pritzker10% owner | Sold | 16,300 | $24.74 | $0.4M | Form 4 |
| Aug 24, 2026 | David R PelizzonDirector, 10% owner | Sold | 4,000 | $25.75 | $0.1M | Form 4 |
| Aug 24, 2026 | Jennifer N. Pritzker10% owner | Sold | 4,000 | $25.75 | $0.1M | Form 4 |
| Mar 16, 2026 | Fred HiteCOO and CFO, Director | Sold | 12,993 | $17.25 | $0.2M | Form 4 |
| Mar 16, 2026 | Joseph W HauserPres. Trauma & Def. Correction | Sold | 8,596 | $17.25 | $0.1M | Form 4 |
| Mar 16, 2026 | Gregory A OdlePresident of Scoliosis | Sold | 8,433 | $17.25 | $0.1M | Form 4 |
| Mar 16, 2026 | Daniel J GerritzenGeneral Counsel and Secretary | Sold | 8,614 | $17.25 | $0.1M | Form 4 |
| Mar 16, 2026 | David R BaileyPresident and CEO, Director | Sold | 19,535 | $17.25 | $0.3M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Orthopediatrics Corp owes $45.2M more than it holds in cash.
Cash, debt and the ratios that show how comfortably Orthopediatrics Corp can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $53.5M | $118M | $80.3M | $68.8M | $60.9M |
| Debt incl. finance leases | $1.0M | $0.9M | $11.1M | $77.5M | $106M |
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.2x | 0.3x |
| Interest coverage | β321.9x | β10.5x | β | β13.4x | β6.5x |
| Current ratio | 4.5x | 7.3x | 5.4x | 7.0x | 5.6x |
| Quick ratio | 2.6x | 4.8x | 2.9x | 3.5x | 2.7x |
| Total assets | $304M | $428M | $439M | $473M | $509M |
| Total liabilities | $78.9M | $49.1M | $61.7M | $119M | $162M |
| Shareholders' equity | $225M | $379M | $377M | $355M | $347M |
| Net debt (β = net cash) | β$52.5M | β$117M | β$69.2M | $8.7M | $45.2M |
KIRA Β· Its return on capital was β7.9%: every 100 invested in the business earned about β8 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Orthopediatrics Corp passes 4 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 9 | 3 / 9 | 3 / 9 | 3 / 9 | 4 / 9 | 4 / 9 | 2 / 9 | 3 / 9 | 4 / 9 |
| Accruals ratio | β17.8% | β3.0% | 3.7% | 2.7% | β5.7% | β1.0% | 6.3% | 1.4% | β2.4% | β7.1% |
| Altman Z'' | β9.52 | 1.14 | 4.05 | 5.24 | 3.20 | 2.93 | 9.36 | 7.30 | 3.84 | 2.68 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $37.3M | $45.6M | $57.6M | $72.6M | $71.1M | $98.0M | $122M | $149M | $205M | $236M |
| Net interest income | β | β | β | β$3.5M | β$3.4M | β$2.2M | β$2.4M | $0.2M | β | β |
| Gross profit | $26.4M | $34.5M | $42.7M | $54.6M | $55.0M | $73.4M | $90.7M | $111M | $149M | $173M |
| Research and development | $2.2M | $3.4M | $4.7M | $5.7M | $5.3M | $5.5M | $8.5M | $10.9M | $11.0M | $9.1M |
| Operating income | β$6.1M | β$6.5M | β$9.6M | β$9.1M | β$26.8M | β$18.0M | β$25.4M | β$26.8M | β$35.0M | β$39.2M |
| Interest expense | $1.5M | $2.5M | $2.3M | $3.5M | $3.4M | $0.1M | $2.4M | β$0.2M | $2.6M | $6.0M |
| Pretax income | β | β$9.0M | β$12.0M | β$12.7M | β$33.7M | β$17.4M | β$3.7M | β$21.3M | β$41.9M | β$39.2M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | β$0.7M | β$1.1M | β$4.9M | β$0.3M | β$4.1M | $0.5M |
| Net income | β$6.6M | β$8.9M | β$12.0M | β$13.7M | β$32.9M | β$16.3M | $1.3M | β$21.0M | β$37.8M | β$39.6M |
| Net income to common | β$12.4M | β$23.5M | β$12.0M | β$13.7M | β$32.9M | β$16.3M | $1.2M | β$21.0M | β$37.8M | β$39.6M |
| Diluted EPS | β$7.14 | β$5.86 | β$0.96 | β$0.94 | β$1.82 | β$0.84 | $0.06 | β$0.92 | β$1.64 | β$1.69 |
| Diluted shares | 0.00B | 0.00B | 0.01B | 0.01B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B |
| Cash flow | ||||||||||
| Cash from operations | β$1.1M | β$7.2M | β$15.6M | β$17.8M | β$18.5M | β$13.1M | β$21.8M | β$27.0M | β$27.0M | β$4.9M |
| Capital expenditure | $4.3M | $5.2M | $5.3M | $11.8M | $10.5M | $8.1M | $10.0M | $16.9M | $14.3M | $11.1M |
| Free cash flow | β$5.5M | β$12.4M | β$20.8M | β$29.6M | β$29.0M | β$21.2M | β$31.8M | β$43.9M | β$41.3M | β$16.0M |
| Depreciation and amortization | $1.9M | $2.4M | $2.9M | $4.7M | $8.0M | $10.7M | $13.1M | $17.4M | $19.1M | $21.1M |
| Stock-based compensation | $1.3M | $3.5M | $3.2M | $2.6M | $6.2M | $5.8M | $6.7M | $10.5M | $13.5M | $17.8M |
| Acquisitions | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $20.2M | $0.0M |
| Dividends paid | $0.0M | $6.0M | $0.0M | $0.0M | β | β | β | β | β | β |
| Dividends and buybacks | $0.0M | $6.0M | $0.0M | $0.0M | β | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $1.6M | $42.6M | $60.7M | $70.8M | $83.9M | $53.5M | $118M | $80.3M | $68.8M | $60.9M |
| Total debt | $17.5M | $25.5M | $21.3M | $26.2M | $1.2M | $1.0M | $0.9M | $11.1M | $77.5M | $106M |
| Current assets | $20.8M | $69.6M | $97.2M | $128M | $158M | $134M | $227M | $226M | $237M | $256M |
| Current liabilities | $7.3M | $9.5M | $9.2M | $13.7M | $35.0M | $29.7M | $30.9M | $41.7M | $34.0M | $46.2M |
| Inventory | β | β | $25.7M | $38.0M | $53.0M | $57.6M | $78.2M | $106M | $117M | $134M |
| Property and equipment, net | $8.6M | $10.4M | $12.8M | $21.3M | $27.2M | $28.5M | $34.3M | $41.0M | $50.6M | $49.6M |
| Goodwill | β | β | $0.0M | $13.8M | $70.5M | $72.3M | $86.8M | $83.7M | $93.8M | $109M |
| Intangible assets | $1.3M | $2.3M | $2.2M | $14.5M | $50.3M | $55.5M | $65.0M | $69.3M | $64.4M | $64.8M |
| Total assets | $30.7M | $82.3M | $112M | $182M | $320M | $304M | $428M | $439M | $473M | $509M |
| Total liabilities | $24.7M | $34.8M | $30.4M | $39.8M | $85.6M | $78.9M | $49.1M | $61.7M | $119M | $162M |
| Shareholders' equity | β$65.3M | $47.5M | $81.7M | $142M | $235M | $225M | $379M | $377M | $355M | $347M |
| Margins | ||||||||||
| Gross margin | 70.7% | 75.5% | 74.2% | 75.3% | 77.4% | 74.9% | 74.1% | 74.8% | 72.6% | 73.1% |
| Operating margin | β16.4% | β14.2% | β16.6% | β12.5% | β37.6% | β18.4% | β20.8% | β18.0% | β17.1% | β16.6% |
| EBITDA margin | β11.3% | β8.9% | β11.6% | β6.1% | β26.4% | β7.5% | β10.1% | β6.3% | β7.8% | β7.7% |
| Net margin | β17.6% | β19.6% | β20.9% | β18.9% | β46.3% | β16.6% | 1.0% | β14.1% | β18.5% | β16.8% |
| FCF margin | β14.7% | β27.2% | β36.2% | β40.8% | β40.8% | β21.6% | β26.0% | β29.5% | β20.2% | β6.8% |
| Net interest share of revenue | β | β | β | β4.9% | β4.8% | β2.3% | β2.0% | 0.1% | β | β |
| Returns | ||||||||||
| Return on capital | β | β16.8% | β17.8% | β7.3% | β13.9% | β8.2% | β7.7% | β6.9% | β7.6% | β7.9% |
| Return on capital employed | β26.2% | β8.9% | β9.3% | β5.4% | β9.4% | β6.6% | β6.4% | β6.7% | β8.0% | β8.5% |
| Return on equity | β | β | β18.6% | β12.3% | β17.5% | β7.1% | 0.4% | β5.6% | β10.3% | β11.3% |
| Return on assets | β21.4% | β15.8% | β12.4% | β9.3% | β13.1% | β5.2% | 0.3% | β4.8% | β8.3% | β8.1% |
| Return on tangible equity | β | β52.1% | β15.1% | β12.0% | β28.9% | β16.7% | 0.5% | β9.4% | β19.3% | β23.0% |
| Growth | ||||||||||
| Revenue growth | β | 22.3% | 26.2% | 26.0% | β2.0% | 37.9% | 24.7% | 21.6% | 37.6% | 15.4% |
| Net income growth | β | β | β | β | β | β | β | β1,767.2% | β | β |
| EPS growth | β | β | β | β | β | β | β | β1,633.3% | β | β |
| Share count change | β | 130.3% | 212.8% | 16.4% | 23.5% | 6.7% | 8.7% | 8.2% | 1.8% | 1.7% |
| Financial health | ||||||||||
| Debt / equity | β | 0.5x | 0.3x | 0.2x | 0.0x | 0.0x | 0.0x | 0.0x | 0.2x | 0.3x |
| Interest coverage | β4.2x | β2.6x | β4.2x | β2.6x | β7.8x | β321.9x | β10.5x | β | β13.4x | β6.5x |
| Current ratio | 2.9x | 7.3x | 10.5x | 9.4x | 4.5x | 4.5x | 7.3x | 5.4x | 7.0x | 5.6x |
| Quick ratio | 2.9x | 7.3x | 7.8x | 6.6x | 3.0x | 2.6x | 4.8x | 2.9x | 3.5x | 2.7x |
| Capital allocation | ||||||||||
| Capex / revenue | 11.7% | 11.4% | 9.1% | 16.3% | 14.8% | 8.3% | 8.2% | 11.3% | 7.0% | 4.7% |
| Stock comp / revenue | 3.4% | 7.6% | 5.5% | 3.6% | 8.7% | 6.0% | 5.5% | 7.1% | 6.6% | 7.5% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 3.0 | 3.0 | 3.0 | 4.0 | 4.0 | 2.0 | 3.0 | 4.0 |
| Altman Z'' | β9.5 | 1.1 | 4.1 | 5.2 | 3.2 | 2.9 | 9.4 | 7.3 | 3.8 | 2.7 |
| Accruals ratio | β17.8% | β3.0% | 3.7% | 2.7% | β5.7% | β1.0% | 6.3% | 1.4% | β2.4% | β7.1% |
Source: SEC EDGAR XBRL filings (CIK 0001425450). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
